Haoyuan Pharmaceutical released its 2026 semi-annual report on the evening of August 26. In the first half of the year, it achieved attributable net profit of approximately 171 million yuan, a year-on-year increase of 12.81%. During the reporting period, the company achieved operating revenue of approximately 1.648 billion yuan, a year-on-year increase of 25.71%. Among this, revenue from the front-end life science reagents business was approximately 1.212 billion yuan, up 34.03% year-on-year; revenue from specialty active pharmaceutical ingredients, intermediates, and formulations was approximately 425 million yuan, up 6.45% year-on-year. The company's main businesses include research and development of life science reagents in the drug discovery field, as well as drug research and development, process optimization, and commercial production of active pharmaceutical ingredients, intermediates, starting materials, and formulations.
Shanghai Haoyuan Chemexpress Co. Ltd. AFirst-half attributable net profit up 12.81% year-on-year, with revenue up 25.71%.
